Rznomics, a leader in RNA-based gene therapeutics, and GluGene Therapeutics, an innovator in Adeno-Associated Virus (AAV) vector engineering, have entered into a strategic collaboration to develop next-generation RNA gene therapies.
The two companies announced on the 23rd that they have signed a Strategic Memorandum of Understanding (MOU) for the development of AAV-based, precision-targeted RNA gene therapies.
At the core of this partnership is the integration of Rznomics’ proprietary RNA trans-splicing ribozyme-based editing platform with GluGene Therapeutics’ AI-driven discovery technology for next-generation AAV vectors. The collaboration aims to co-develop precision gene therapy solutions that enhance target cell selectivity and delivery efficiency while prioritizing patient convenience and accessibility.
The AAV vector is currently recognized as a commercially validated platform for gene therapy, with a significant portion of FDA-approved gene therapies utilizing AAV delivery systems. Market research indicates that the global AAV gene therapy market is projected to grow at a CAGR of approximately 26%, reaching a valuation of $23.5 billion by 2034.
Despite its success, the field faces ongoing translational challenges, including payload size constraints, the need for enhanced tissue specificity, minimization of immune responses, and the requirement for high-efficiency delivery at lower doses. The two companies plan to leverage AI-guided vector design to overcome these technical limitations and improve the accessibility of RNA-based precision medicine.
Furthermore, the partnership will explore the expansion of their combined platforms into broader indications, including genetic disorders and central nervous system (CNS) diseases.
Seong-Wook Lee, CEO of Rznomics, stated, “Through our collaboration with GluGene Therapeutics, we intend to strengthen the therapeutic competitiveness and scalability of our RNA platform. Our development focus remains on improving treatment convenience and patient access.”
Moon Sue Lee, CEO of GluGene Therapeutics, added, “This partnership serves as a significant opportunity to validate the value of our data-driven, precision-targeted AAV platform. By leveraging the technological synergies between our companies, we aim to expand our footprint within the global gene therapy market.”
https://www.mk.co.kr/news/it/11968864
